Deciphera Pharmaceuticals company information, Employees & Contact Information

Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) Yahoo Finance

European Commission Green-Lights Vimseltinib for Symptomatic, Unresectable TGCT OncLive

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025 FinancialContent

Ono goes for growth with $2.4bn Deciphera buy | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company Stock Titan

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn Pharmaceutical Technology

Deciphera Pharmaceuticals Announces Second Quarter 2022 Financial Results citybiz

Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement PR Newswire

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial Nature

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion Business Wire

Vimseltinib Earns Positive CHMP Recommendation for TGCT OncLive

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals PR Newswire

Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results Business Wire

Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company Business Wire

Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study Business Wire

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT) Business Wire

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) Business Wire

Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment PR Newswire

FDA approves Deciphera’s Romvimza for rare tumour type PharmaTimes

FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout Fierce Pharma

Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) PR Newswire

Ono Acquires Deciphera Pharmaceuticals Contract Pharma

Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FinancialContent

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences FinancialContent

Diving Into Deciphera Pharmaceuticals (NASDAQ:DCPH) Seeking Alpha

Japan's Ono pays $2.4B for Qinlock maker Deciphera as biotech readies another approval run Fierce Pharma

Ono Pharma’s Plan to Become a Global Player Picks Up a New Piece With $2.4B Deciphera Acquisition MedCity News

Fierce Pharma Asia—Ono buys Deciphera for $2.4B; Novartis expands PeptiDream collab; WuXi Bio exits BIO 2024 Fierce Pharma

Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint BioSpace

After flunking key trial, Deciphera cuts 140 jobs, halts development of two drugs Fierce Pharma

After Phase 3 failure busts blockbuster bid, Deciphera restructures; staff slashed 35% MedCity News

Deciphera misses blockbuster opportunity as Qinlock fails to top Pfizer's Sutent in rare stomach cancer Fierce Pharma

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17 FinancialContent

Ono swoops on Deciphera in $2.4 billion takeover pharmaphorum

Greenberg, Goodwin shepherd Ono Pharma’s $2.4bn Deciphera acquisition The Global Legal Post

The top 10 takeover targets in biopharma Fierce Biotech

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial BMC Cancer

Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China NAI500

Hoerter to replace Taylor as CEO of Deciphera Fierce Biotech

Deciphera CBO Morl talks lines of therapy for kinase inhibitor ripretinib Fierce Biotech

Deciphera fills in where Blueprint falls short with early FDA nod in rare stomach cancer Fierce Pharma

Japan's Ono Pharma to buy U.S. drugmaker Deciphera for $2.4bn Nikkei Asia